Stifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $33.00 (from $49.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - MizuhoMay 19, 2021 12:42 PM Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA DelayMay 19, 2021 7:58 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $48 at Truist SecuritiesMay 19, 2021 7:04 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $40 at BarclaysMay 19, 2021 5:34 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at OppenheimerMay 19, 2021 5:07 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $93 at Goldman SachsMay 19, 2021 3:40 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $43 at JMP SecuritiesMay 19, 2021 1:54 AM After-Hours Stock Movers 05/18: (LPTH) (PRPL) (TTWO) Higher; (IOVA) (QUIK) (LAD) Lower (more...)May 18, 2021 5:52 PM Iovance Biotherapeutics (IOVA) Provides Regulatory Update for Lifileucel Potency Assays, BLA Submission Now Expected H1 2022May 18, 2021 4:31 PM